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Purpose: The primary objective of the study was to investigate the possible inhibition of cataract formation by topical
administration of caffeine using the galactosemic rat model. It was hypothesized that caffeine will do so by acting as
scavenger of reactive oxygen species known to be generated under hyperglycemic conditions.
Methods: Cataract was induced by feeding young rats a diet containing 24% galactose for a period of 25 days. A control
group of such rats was treated with a placebo eye drop preparation containing hydroxy propyl methyl cellulose as a wetting
agent. In the experimental group, the rats were treated with the above preparation mixed with 72 mM caffeine.
Results: Administration of caffeine eye drops was found to significantly inhibit the onset as well as the progress of cataract
formation. By day 25 on the galactose diet, all the animals in the control group developed advanced white opacity spread
over the entire area of the lens. In the caffeine group, the formation of such opacity remained strikingly inhibited. The
lenses remained largely transparent. The transparency data paralleled the higher concentration of glutathione maintained
by caffeine treatment. Its levels in the placebo group were 0.8, 0.5, and 0.4 µmoles/g lens wt. on days 5, 15, and 25 against
a consistent basal control value of ~3 µmoles/g over the entire period. In the caffeine group, the corresponding values
were nearly 3 µmoles/g till day 15, but decreasing to ~2 µmoles/g on day 25. The levels were hence significantly higher
than in the caffeine untreated group, remaining relatively closer to the basal controls. In addition, the compound was found
effective in inhibiting morphological changes induced by galactose.
Conclusions: Micromolar amounts of topical caffeine have been found to be significantly effective in inhibiting the
formation of galactose cataract, strongly suggesting its possible usefulness against diabetic cataracts. The effects are
attributed to its ability to prevent oxidative stress and consequent maintenance of tissue metabolic and transport functions,
in addition to preventing the induction of apoptosis.
Caffeine  is  one  of  the  most  common  nutraceuticals
derived from many common beverages such as coffee, tea and
various colas. In addition, it is a common food additive such
as that in chocolates, cakes, and candies and some other food
products.
Conservatively, the average human consumption of this
alkaloid  derived  from  coffee  drinking  alone  ranges  from
approximately 250–400 mg per day, the concentration in an
average  cup  of  coffee  being  about  200  mg/12  ounce  [1].
Additional significant amounts are derived from soft drinks
and tea. The US Food and Drug Administration (FDA) lists
this as a generally safe compound for human consumption,
the LD50 being substantially high (10 to 15 g of a single dose)
[2], equivalent to 80–100 cups of coffee. Achieving lethality
is difficult. Additionally, regular use of this compound, mostly
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derived from coffee drinking, has been reported to provide
several very significant health benefits such as the reduced
incidence of of Alzheimer and Parkinson disease [3-7], senile
dementia, and prevention of neural degeneration in general
and associated loss of cognitive performance [8-10]. Recent
reports  also  suggest  that  it  decreases  the  risk  of  the
development of Type 2 diabetes [11,12] loss of liver function
and cirrhosis [13,14] and certain cancers [15-20]. Previous
reports  suggesting  an  association  between  regular  use  of
caffeine  and  development  of  hypertension  has  also  been
significantly toned down in view of recent epidemiological
findings. The association between hypertension and coffee
intake could not be established in a study based on at least
155,000 nurses [21]. A Harvard study with 128,000 people
concluded that coffee consumption is also not associated with
coronary heart disease unless it is used in combination with
cigarette smoking and excessive use of alcohol [22]. These
and  many  other  such  positive  reports  point  out  to  the
desirability of further studies on the mechanism of action of
this  ubiquitously  prevalent  nutraceutical.  Interestingly,
studies  on  its  possible  beneficial  and  therapeutic  effects
against the aging eye diseases have been very limited except
some  recent  preliminary  reports  from  this  laboratory
suggesting  that  it  has  a  potential  to  slow  down  cataract
progression. The suggestion has been based on the in vitro
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2626organ  culture  experiments  showing  its  effectiveness  in
offering  protection  against  lens  damage  caused  by  UV
exposure, as reflected by the severe inhibition of the active
cation transport process as well as the depletion of GSH.
Incorporation  of  caffeine  in  the  culture  medium  protects
against the induction of these deleterious effects [23,24]. It
also prevents the loss of tissue transparency associated with
UV exposure. Such a loss of transparency in vivo would
directly interfere with transmission and refraction of light
coming  into  the  eye  and  its  focusing  on  the  retina.
Interestingly, in a preliminary study, caffeine has also been
shown to prevent phototoxic damage to retina [25]. The anti-
cataractogenic  potential  of  the  compound  in  vivo  is
suggestible  also  by  preliminary  studies  showing  that
formation of cataracts in rats maintained on a high galactose
(24%) diet is significantly inhibited if the galactose diet is
fortified with 1% caffeine [26]. However, to rule out the
possibility that such an effect of caffeine could have been
systemic in nature, it was considered necessary to investigate
if caffeine could be effective when administered topically in
the form of eye drops. Also, such topical application of the
compounds  is  well  known  to  enhance  their  local
pharmacological effects in the eye, in addition to avoiding any
unwanted systemic effects.
METHODS
Most of the routine chemicals used were procured from Sigma
Aldrich Chemical Company, St. Louis, MO. N-methyl-14C-
caffeine  was  obtained  from  Perkin  Elmer,  Boston,
Massachusetts (Catalog # NEC4120; Perkin Elmer). DAPI (4',
6’-diamidine-2-phenylindole)  was  obtained  from  Roche
Diagnostics,  Indianapolis,  IN.  Fluorescein-12-dUTP
(Fluorescein-5(6)-carboxaminocaproyl-[5-(3-aminoallyl)-2
´-deoxy-uridine-5′-triphosphate)  was  obtained  from  Life
Technology,  Carlsbad,  CA.  Sprague  Dawley  rats  were
obtained from Harlan Laboratories, Indianapolis, IN.
Determination  of  caffeine  penetration  in  the  aqueous
humor and lens: An eye drop preparation was made by adding
hydroxypropyl methyl cellulose (0.9%, 3,000 centipoise) to
72 mM aqueous solution of caffeine water. The placebo was
made  by  substituting  caffeine  with  72  mM  NaCl.  In
penetration studies, 14C1-caffeine was added to above caffeine
solution acting as a tracer. This preparation (20 µl) was then
instilled into the cul-de-sac of six rats kept anesthetized with
ketamine  (80  mg/kg)  and  xylazine  (10  mg/kg).  Aqueous
humor samples were withdrawn from both the eyes at time
points of 30, 60, 120, and 180 min using an insulin syringe.
The aqueous samples withdrawn were transferred to a conical
microfuge tube and lightly centrifuged to collect the fluid at
the bottom. Measured volumes (5 µl) of such samples were
then  transferred  to  a  liquid  scintillation  cocktail  (Econo-
safeTM; Research Products International Corporation, Mount
Prospect,  IL)  and  their  radio  activities  determined.  The
concentration  of  the  caffeine  in  the  aqueous  was  then
determined by reference to the specific activity of 14C in the
eye drop preparation which was kept near 250 cpm/nanomole.
The lenses were isolated after taking out the aqueous humor,
rinsed with saline, weighed and then homogenized in 75 µl of
water. The homogenates were then quantitatively transferred
to the scintillation cocktail vial and radioactivity determined
as above. The amount of caffeine present in the lenses was
then determined with reference to its specific activity in the
eye drop preparation.
Assessment of cataract inhibition: The initial objective of
the study was to ascertain the effectiveness of caffeine eye
drops against development of early cataracts. This was done
by maintaining rats weighing about 50 g on a 24% galactose
diet for 5 days and administering the eye drops containing
caffeine five times a day at 90 min intervals till four days. On
the  fifth  day,  drops  were  given  only  twice,  2  h  before
euthanization.  In  the  control  group  maintained  on  the
galactose diet, the eyes were treated with the caffeine free
placebo drops. The eyes were examined ophthalmoscopically
for  appearance  of  cataracts.  Peripheral  cortical  cataracts
became visible in all the placebo treated animals by day 4. On
day 5, the animals were euthanized by CO2 inhalation, eyes
were then enucleated and lenses dissected out by posterior
approach and transferred to saline maintained at 37 °C till
photographic documentation of cataract. The time between
isolation of the lens and photography was less then 15 min.
The photographs were taken after placing the lenses on a
Millipore metallic grid using transillumination.
Subsequent  experiments  were  then  conducted  to
ascertain the possibility of delaying the formation of cataracts
even  further  by  such  topical  application.  Hence  in  these
experiments, treatment with the placebo or the caffeine eye
drops was continued for either 15 or 25 days. The number of
animals in each group was at least six. Lenses were then
isolated as described above. One lens isolated from each of
the animals was quickly frozen for later determination of
glutathione  (GSH).  The  contralaterals  were  used  for
photography  as  described  above.  A  semi  quantitative
assessment of the densitiy of opacity as present on day 25 was
also done by Adobe photoshop (Adobe Systems Inc., San
Jose, CA) using program number CS3.
Random samples of lenses after photography on day 15
were fixed in PBS buffered 10% formalin and subsequently
paraffin embedded for sectioning. The microtome sections
were  then  stained  with  H&E  for  examining  the  general
structure of the tissue. The distribution pattern of the nucleated
cells was monitored by staining with DAPI. The presence of
apoptotic cells was detected by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining based
on terminal deoxynucleotidyl transferase catalyzed labeling
of the 3′-OH of the damaged DNA with fluorescein-12-dUTP.
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Since the objective of these experiments was to determine if
caffeine would be effective in inhibiting cataract formation
when applied topically, initial experiments were designed to
study the extent of its penetration through the cornea into the
aqueous and the lens after its topical application in the form
of an eye drop. Such information was not available in the
literature.  The  amount  of  caffeine  contained  in  the  drop
applied (20 µl) was 279 µg. In case of its theoretical 100%
availability and its distribution in the aqueous humor with a
normal volume of ~10 µl, the resulting aqueous concentration
would be ~144 mM. However, as expected, this was not the
case due to the inherent unavailability of the entire amount
instilled because of the animals closing their eyes after the
application of the drops at room temperature (even though
under mild anesthesia) and consequent expulsion and leakage
of  significant  portions  of  the  applied  drops  through  the
palpebral fissure and the nasolacrimal duct. However, the
application  was  found  adequate  enough  to  raise  caffeine
concentration significantly in the aqueous as well as in the
lens. As summarized in Figure 1, the aqueous levels were
3.9,10, 3.8, and 1.8 mM at 30, 60, 90, and 120 min time points.
The corresponding levels in the lens were 1.8, 6, 2.4, and
2  mM.  Based  on  the  previous  in  vitro  studies  showing
inhibition of the ROS induced damage to the lens by caffeine
[23,24], these levels were considered adequate for judging its
Figure 1. Intraocular penetration of Caffeine in aqueous and lens.
Twenty microliters of the caffeine eye drop preparation labeled with
14C1-caffeine was instilled in the eyes of anesthetized rats. Samples
of  aqueous  were  prepared  as  described  in  the  text  and  their
radioactivity  determined  by  liquid  scintillation  counting.  The
concentrations of the caffeine were then calculated with reference to
the specific activity of caffeine in the eye drop. The results are
described as Means of four aqueous and four lens samples. The
standard deviation at each point was less than 0.35 mM.
effectiveness in inhibiting the cataract formation. That was
indeed found to be true.
As shown in Figure 2A, application of such a drop (no
radioactivity being present in these eye drops) five times a day
to  the  animals  maintained  on  24%  galactose  diet  had  a
significant  inhibitory  effect  on  the  onset  as  well  as  the
progression  of  cataract  formation.  A  well  discernible
equatorial cortical cataract represented by the white peripheral
ring formed in 4 to 5 days in the rats given the galactose diet
and treated only with the placebo eye drops. On the contrary,
in the group where animals were treated with the caffeine eye
drops, development of such opacity was nearly completely
abolished, the lenses remaining essentially clear. The anti-
cataractogenic effect of caffeine was hence more specifically
demonstrated  here  than  that  in  the  earlier  preliminary
experiments  [26]  where  the  galactose  diet  contained  1%
caffeine. The present experiments therefore effectively rule
Figure 2. Cataract development in galactose fed rats. Preventive
effect of caffeine. At various stages of cataract development the
animals were euthanized by CO2 inhalation, lenses dissected out and
placed on a Millipore metallic grid with uniform holes. Photographs
were  then  taken  in  dark  with  retro-illumination.  A:  Cataract  is
indicated by the obstruction in light transmission through the grid
holes because of the noticed opacity. B: Semiquantitaive evaluaton
of the density of opacity (G: galactose diet; C: caffeine treated).
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observed  earlier  could  have  been  a  systemic  effect.  In
addition, the effectiveness of the caffeine noticed by topical
administration of only micro molar amounts of caffeine points
out further its pharmacological suitability and rules out the
possibility of any toxicity when used topically.
Hence the above investigations were extended further to
examine if the anticataractogenic effect, as observed in the
early  stages  of  galactose  feeding,  can  remain  sustained,
delaying the formation of cataracts even further. Hence in
these experiments treatment with the eye drops were extended
up to 25 days, the time required for complete maturation of
the galactose cataracts in the control (caffeine-free) group. As
shown in Figure 2A, the degree of opacity by day 15 in the
galactosemic animals given the placebo eye drop, as expected,
was  much  more  advanced,  well  marked  and  much  more
extensive than that noted in the short-term experiments where
the experiments were terminated on day 5. The severity of
opacity in the placebo group advanced further by day 25, the
opacity covering the entire lens. On the contrary, in the case
of animals treated with the caffeine eye drops, the lenses were
still transparent. The effectiveness of treatment was further
analyzed  (Figure  2B)  semi  quantitatively  using  Adobe
Photoshop (CS3); showing that the density of opacity in the
lens of the placebo group was about 15 times higher in the
caffeine group. The lenses in the caffeine treated group were
still largely clear except some peripheral opacity not adequate
to hinder any significant light transmission.
Figure 3. Levels of glutathione in the lenses of different groups. The
values are expressed as Means±standard deviation. The depression
of GSH in the galactose alone group as compared to the normal as
well as when compared to the galactose plus caffeine group is highly
significant (p values ≤0.001) at all points of observation. The values
in the galactose plus caffeine group were also significantly higher
than the galactose alone group. By 25 day the GSH value in the
galactose plus caffeine group was lower than in the control groups,
but was still higher than in the galactose alone group and adequate
to maintain lens transparency barring the periphery.
The  preventive  effect  against  opacification  was  also
apparent in terms of the levels of GSH summarized in Figure
3.  In  the  five  day  experiments,  the  level  of  GSH  in  the
galactose fed animals treated with the placebo decreased to
about 24% of the basal controls. In the caffeine treated group
it was more than three times of the placebo group, remaining
still close to 90% of the basal controls. On day 15 also the
levels  in  the  caffeine  group  remained  close  to  the  basal
controls. In the caffeine untreated group the levels remained
depressed to about 15% of the basal controls. On day 25, the
level of GSH was still maintained at a level of 65% of the basal
control, the level in the untreated group being only 12% of the
basal controls. The GSH level in the caffeine treated groups
remained  much  closer  to  the  basal  controls  than  in  the
untreated groups where it underwent a substantial decrease.
The  effect  of  caffeine  was  also  apparent  by  H&E
histology as presented in Figure 4. In the galactosemic group
not treated with caffeine, the subepithelial region including
the deeper cortical region consisted of numerous nucleated
fibers indicative of defective differentiation of the epithelial
cells to fiber cells, the deeper nuclear layer containing much
swollen denucleated cells. The overall structure of this region
is  non-homogenous  represented  by  denser  opacity  as
compared to the cortex, as also apparent in Figure 2. As can
be seen in Figure 4C,D, lenses of the galactosemic animals
treated  with  1.4%  caffeine  eye  drops  (ED)  maintained  a
normal  cellular  structure  consisting  of  a  single  layer  of
epithelial cells followed by well aligned non-nucleated fiber
cells. The central portion of the tissue consisting of compacted
fibers also remained homogenous.
Figure  5  represents  the  sections  stained  with  DAPI
(Figure 5A-D) and F-dUTP (Figure 5E-H). As apparent by the
DAPI staining of the normal lens section (Figure 5A) most of
the nucleated cells are present in the bow zone of the tissue.
Treatment with caffeine eye drops has no effect (Figure 5B),
the  cellular  configuration  remaining  similar  to  the  blank
controls.  On  the  other  hand,  in  the  case  of  galactose  fed
animals  the  distribution  of  the  DAPI  cells  was  highly
abnormal (Figure 5C) with high abundance of the nucleated
cells in the deeper cortex. That these cells indeed are apoptotic
was proven by TUNEL staining using F-dUTP (Figure 5G).
In the lens from galactosemic animals treated with the caffeine
eye drops (Figure 5H), the distribution of the DAPI positive
cells  was  similar  to  that  in  the  normal  non-galactosemic
controls, showing the effectiveness of caffeine in inhibition
of abnormal cell maturation induced by galactose. Apoptotic
cells could also not be detected in the normal controls without
and with caffeine (Figure 5E,F). As shown in Figure 5H,
apoptosis was completely inhibited by the caffeine regimen
of the galactosemic animals. It should be pointed out that
caffeine  has  been  reported  to  induce  apoptosis  in  certain
cancer cells on exposure to high intensity ionizing radiation,
a  process  helpful  in  getting  rid  of  the  cancerous  cells.
However, caffeine does not seem to induce any apoptosis in
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noncancerous cells including that in the cornea and indeed its
effectiveness in inhibiting the apoptosis in the lens indicates
that it is able to inhibit DNA damage caused by oxidative
stress, similar to the effect of pyruvate reported previously.
DISCUSSION
Since oxidative stress induced by reactive oxygen species
plays an important role in the genesis of cataracts, it is highly
likely that its formation can be attenuated or even prevented
by use of certain oxy-radical scavengers. This is strongly
apparent by several in vitro as well as in vivo studies with
animal models. For example, the formation of cataracts in rat
pups induced by oxidative stress triggered by administration
of sodium selenite as an oxidant has been found to be inhibited
by  subcutaneous/intraperitoneal  injection  of  ascorbate,
pyruvate and alpha ketoglutarate [27-29].We have recently
reported that caffeine is also highly effective in preventing
selenite  cataract  formation.  Formation  of  cataracts  in  the
diabetic  and  galactosemic  rats  is  also  prevented  by  oral
administration  of  flavonoids  and  other  aldose  reductase
inhibitors, acting as antioxidants [30,31]. This has also been
found  in  diabetic  mice  where  cataract  development  is
prevented  by  pyruvate  as  an  antioxidant  and  metabolic
stimulant,  independent  of  its  action  as  aldose  reducatase
inhibitor [32-34]. The pharmacological use of most of these
compounds  for  treating  and  preventing  human  cataracts
however still remains to be realized. This is because of their
much higher dilution in the human body when administered
orally  with  the  consequence  of  only  low  concentrations
available in the ocular tissues. In addition they are effectively
metabolized and used by other body tissues before reaching
the eye in adequate concentration. A larger dose may even
have  undesirable  systemic  effects.  While  they  can  be
administered topically, their instability in topical eye drop
preparations is also a significant limiting factor. This is due to
their susceptibility to auto-oxidative degradation. In addition
their auto-oxidation can generate products which can act as
pro-oxidants  and  protein  cross  linkers.  It  is  therefore
considered desirable to examine the feasibility of preventing
cataract formation by oxyradical scavengers that are more
stable, even when incorporated in eye drop preparations and
their reaction products generated by reacting with ROS are
also  not  toxic.  With  this  in  view,  we  are  studying  the
possibility of inhibiting cataract formation by use of caffeine.
The compound is easily available and is much more resistant
to auto-oxidation. Its reaction with ROS is accompanied with
the  formation  of  its  8-hydroxy  derivative  [35-37],  with
structure similar to urate, another ROS scavenger. In addition,
it  is  known  to  be  well  tolerated  by  humans  even  when
consumed in significant amounts as a common nutraceutical
used over the entire life span. Interestingly, its consumptions
has  been  shown  to  provide  several  significant  beneficial
health  effects  mentioned  earlier,  including  its  favorable
effects against nerve damage associated with highly disabling
Alzheimer and Parkinson disease. Oxidative stress is known
to be a causal factor in the etiology of both these diseases; with
the difference that in the case of lens such oxidative stress is
more  pronounced.  This  is  due  to  the  continued  light
Figure  4.  H&E  profile  of  the  lens
sections.  The  upper  panel  (A  and  B)
represents  lenses  in  rats  given  the
galactose  diet  treated  only  with  the
placebo.  Apparent  is  the  retention  of
nucleus in the fiber cells due to defective
cellular transition. The nuclei are also
clearly pyknotic. The central area of the
tissue (B) also contains some nucleated
cells.  Other  cells  are  swollen  and
detached  form  each  other.  These
abnormalities  were  inhibited  in  the
group treated with caffeine eye drops as
shown in the lower panel (C and D).
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vision and the consequent prolonged exposure of the lens to
oxy-radical  species  generated  continuously  by  pseudo
catalytic photochemical reactions [38,39]. We have recently
reported that such damage to the lens in culture induced by
UV irradiation is significantly preventable by caffeine. That
the  preventive  effect  is  due  its  oxy-radical  scavenging
property has been affirmed by ESR studies as well as by
parallel studies with other well established ROS Scavengers
such as Tempol [24]. Additionally, it has been found to protect
lens cultured in dark with ROS generated by incorporation of
soluble  iron  into  the  medium  [40].  Further  studies  are
therefore considered desirable to further ascertain its anti-
cataractogenic effect in vivo.
Encouraged with the earlier preliminary findings [26]
suggesting  that  caffeine  could  inhibit  cataract  formation
induced by high levels of sugars, the present investigations
were  undertaken  to  examine  its  possibility  further  by
administering it directly in an eye drop. This was hypothesized
to be more effective even at doses lower than the oral dose
used  earlier,  with  the  eventual  objective  of  further
pharmacological  evaluation.  It  is  also  hypothesized  to
overcome  the  concern  of  any  undesirable  systemic  effect
possible if used orally in relatively larger amounts. Indeed its
presence  in  coffee  has  been  controversially  suggested  to
transiently elevate the intraocular pressure by 1 to 2 mm in
patients with existing glaucoma [41-43]. However the results
are considered insignificant [42,43]. A deviation of 1 to 2 mM
can take place even after water drinking [44,45]. Indeed, the
potential of caffeine to induce glaucoma has now been well
disproven by a very high powered prospective cohort study
with  79,120  women  and  42,052  men  [46].  A  suggestive
increase of 1–2 mm in the intra-ocular pressure has also been
discounted  because  of  a  normal  variability  of  a  few
millimeters in the measuring technique itself. It should also
be mentioned that coffee and caffeine are not equivalent. A
well recognized scientific study with 400 mg of pure caffeine
administered orally has also been found entirely ineffective in
either raising the intra-ocular pressure or inhibiting aqueous
flow measured by fluorophotometry [47]. Hence the present
findings on the inhibition of cataract formation by caffeine are
considered  to  provide  adequate  base  line  information  for
further  studies  with  view  points  of  pharmacology  and
toxicology.  The  importance  of  scavenging  ROS  and
maintaining GSH levels has been previously suggested also
by  several  previous  papers  [48,49].  Examination  of  the
effectiveness of caffeine against cataract formation was done
by topical application of 279 μg of caffeine administered 5
times a day. Hence the amount administered each time was
much less than even the LD50 of 200 mg/kg to rats required
Figure 5. Induction of apoptosis. Prevention by caffeine. The pictures represent the sections of the lens stained with DAPI (A-D) and F-UTP
(E-H) Sections A and E represent normal lenses. Sections B and F represent the lenses from normal rats treated with caffeine eye drops.
Sections C and G represent lenses from galactose group treated with placebo. Sections D and H represent caffeine treated group. Photographs
C and G indicate defective transformation of the epithelial cells into fiber cells, indicated by retention of nuclei and/or apoptosis. Sections
D and H prove that caffeine inhibits such apoptotic process.
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rats was 50 g. Hence, the total dose given per day was only
1.4 mg. This was also much lower than LD50. Only a small
fraction of this actually got into the aqueous humor. As shown
graphically in Figure 1, despite application of caffeine in such
small amounts, cataract formation was dramatically inhibited.
In the animals treated with the placebo eye drops, the early
cataract in the form of equatorial and cortical opacity was
notable by 4th to 5th day after putting the animals on the
galactose diet, similar to that reported previously. This was
significantly absent in the group given the caffeine eye drops.
As expected, by day 15 the cataract became much advanced
in placebo group, the opacity in these lenses being more severe
and covering a much larger area of the lens, as compared to
that on day 4. In addition to the presence of clearly white
opacity, covering at least 50% of the lens surface or more,
other areas also became hazy as apparent photographically.
But in the group treated with the caffeine eye drop, lenses were
still  largely  transparent  without  any  significant  haze  or
opacity.  The  protective  effect  remained  sustained  by
continued treatment at least till 25 days when the experiments
were terminated.
Caffeine has previously been reported to induce cellular
apoptosis  in  some  experimental  conditions  such  as  on
incubation  of  certain  transformed  cancerous  cells.  It  was
therefore  considered  important  to  examine  the  possible
presence of such apoptotic cells in the lenses of the placebo
and caffeine treated groups. As expected no apoptotic cells
were detected in the animals on galactose free diet. In the
galactose fed group however, significant number of cells were
TUNEL  positive.  However,  in  the  caffeine  treated  group,
apoptotic cells were not detected, as previously shown in
cornea [50]. The results therefore clearly demonstrate that
caffeine does not induce apoptosis in lenses. In addition, it
also  stops  the  apoptotic  process  associated  normally  with
cataract formation including that in diabetes [34]. Since oxy-
radical formation is well known to induce DNA damage, it is
highly  likely  that  the  TUNEL  positive  cells  in  the
galactosemic lenses represent DNA damage caused by its
oxidative stress. The preventive effect of caffeine is therefore
apparently related to its ability to detoxify reactive oxygen
generated under hyperglycemic condition. The significance
of other modes of its action such as its effect of maintaining
higher levels of c-AMP by inhibiting phosphodiesterase in the
lens remains to be verified at present. However, the findings
that caffeine prevents cataract formation induced by a strongly
potent cataractogenic agent such as galactose in vivo and
against UV induced ROS damaged noted earlier suggest the
suitability of its use pharmacologically, particularly as an eye
drop for cataract prevention or delay. The agent as used is
hypothesized not to be toxic also in view of the well known
human tolerance to this and other similar alkaloids. Further
mechanistic  and  pharmacokinetic  studies  are  hence  in
progress, including studies with the diabetic models.
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